AstraZeneca AZNannounced that the FDA has approved Lokelma (sodium zirconium cyclosilicate) formerly known as ZS-9, for the treatment of hyperkalemia in adults. Hyperkalemia is a serious condition characterized by high levels of potassium in the blood and Lokelma is a highly selective, oral potassium-removing agent.
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться